文献速递胸部肿瘤

Deulorlatinib(TGRX-326)用于二代ALK抑制剂耐药后ALK阳性NSCLC:单臂多中心2期试验

Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial.
PubMed 文献 · J Thorac Oncol · 2026-04-22

这项在中国36个中心开展的单臂2期试验评估了三代ALK抑制剂deulorlatinib 60 mg每日一次用于二代ALK抑制剂治疗失败的ALK阳性NSCLC患者。独立评审委员会评估的客观缓解率为43.7%,中位无进展生存期为11.1个月,可测量中枢神经系统转移患者颅内客观缓解率为55.8%,携带G1202R突变患者亦观察到较强活性,安全性总体可控。

要点

  • 二代ALK抑制剂失败后ORR达43.7%,中位PFS为11.1个月
  • 可测量CNS转移患者颅内ORR为55.8%
  • G1202R突变患者ORR 62.5%,DCR 100%

核心结论

  • Deulorlatinib在二代ALK抑制剂治疗失败的晚期ALK阳性NSCLC中显示出令人鼓舞的抗肿瘤活性,包括G1202R突变患者。
  • 鉴于其良好的安全性特征,deulorlatinib有望成为该人群的新治疗选择。

研究设计与样本

  • 单臂、多中心2期试验(NCT05955391),在中国36个中心开展。
  • 入组患者接受deulorlatinib 60 mg每日一次口服。
  • 疗效分析集158例,安全性分析集163例。
  • 主要终点为独立评审委员会评估的客观缓解率,关键次要终点包括疾病控制率、无进展生存期、缓解持续时间、总生存期、颅内疗效和安全性。
  • 采用游离DNA进行探索性生物标志物分析。

主要发现

  • 独立评审委员会评估的ORR为43.7%(95%CI 35.8-51.8),达到主要终点。
  • 独立评审委员会评估的中位PFS为11.1个月(95%CI 8.3-13.7)。
  • 可测量中枢神经系统转移患者(n=43)颅内ORR为55.8%(95%CI 39.9-70.9)。
  • G1202R突变患者(n=8)ORR为62.5%,疾病控制率100%,中位PFS 11.0个月。
  • 研究者评估结果与独立评审委员会评估结果一致。

关键数值与推荐

  • 治疗相关不良事件发生率96.3%,≥3级占47.2%。
  • 剂量调整不频繁:中断13.5%,减量11.0%,永久停药0.6%。
  • 中枢神经系统相关治疗相关不良事件发生率为12.9%,无患者因中枢神经系统毒性中断或停止治疗。

临床怎么用

  • 对于二代ALK抑制剂治疗失败的ALK阳性NSCLC患者,deulorlatinib 60 mg每日一次提供了具有临床意义的活动性。
  • 对存在可测量中枢神经系统转移或G1202R突变的患者,该药显示出尤其值得关注的疗效信号。
  • 治疗相关不良事件常见但剂量调整率低,中枢神经系统毒性未见导致治疗中断,支持其临床可管理性。

局限性

  • 单臂设计,无对照组,结论需谨慎解读。
  • G1202R突变亚组样本量小(n=8),结果需进一步验证。
  • 研究仅在中国进行,人群代表性有限。
  • 随访时间及总生存数据尚未成熟(原文未报告)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Deulorlatinib (TGRX-326), a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor, has reported promising activity and a favorable safety profile in ALK-positive NSCLC in a phase 1 trial. Here, we report the primary results of the pivotal phase 2 trial (NCT05955391) evaluating deulorlatinib in patients with ALK-positive NSCLC in whom second-generation ALK inhibitors had failed. METHODS: This single-arm, phase 2 trial was conducted at 36 centers in China. Eligible patients received deulorlatinib 60 mg once daily. The primary end point was objective response rate (ORR) assessed by an independent review committee (IRC). Key secondary end points included disease control rate, progression-free survival (PFS), duration of response, overall survival, intracranial efficacy, and safety. Exploratory biomarker analyses were performed using cell-free DNA. RESULTS: The efficacy and safety analysis sets comprised 158 and 163 patients, respectively. The primary end point was met with an IRC-assessed ORR of 43.7% (95% confidence interval [CI], 35.8-51.8). The IRC-assessed median PFS was 11.1 months (95% CI, 8.3-13.7). Among patients with measurable central nervous system (CNS) metastases (n = 43), the intracranial ORR was 55.8% (95% CI, 39.9-70.9). In patients harboring the G1202R mutation (n = 8), robust activity was observed (ORR: 62.5%; disease control rate: 100%; median PFS: 11.0 months). The investigator-assessed results were consistent with the IRC-assessed findings. Treatment-related adverse events occurred in 96.3% of patients (47.2% grade ≥3). Nevertheless, dose modifications were infrequent (interruption, 13.5%; reduction, 11.0%; permanent discontinuation, 0.6%). The incidence of CNS-related treatment-related adverse events was 12.9%, with no patients interrupting or discontinuing treatment owing to CNS toxicity. CONCLUSIONS: Deulorlatinib indicated encouraging antitumor activity in patients with advanced ALK-positive NSCLC after failure of second-generation ALK inhibitors, including those with the G1202R mutation. Given its favorable safety profile, deulorlatinib represents a promising new option for this population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Huang J, Chen G, Wang Z, et al. Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial. J Thorac Oncol. 2026. PMID: 42031067. doi:10.1016/j.jtho.2026.103737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。